journal article·2026-02Open access

Multimodal cascade-amplified phototheranostics for enhanced anti-tumor immunity

Liang Chen, Jierou Huang, Li Liu, Ming Tong, Xinchun He, Shaojing Zhao, Qingxu Diao, Haiou Chen, Jie Zeng, Minhuan Lan, Jianing Yi

Biomaterials· Volume 325

Abstract

Effective immuno-photodynamic therapy (IPDT) is impeded by the limitations of monotherapy approaches, inadequate immune activation, and an immunosuppressive tumor microenvironment (TME). Here, we present a multifunctional phototheranostic nanoplatform based on an A-D-A type photovoltaic molecule (ITCC), which self-assembles into water-soluble nanoparticles (ITCC NPs) via DSPE-PEG–NH 2 –2000. Upon near-infrared (NIR) irradiation, ITCC NPs generate reactive oxygen species (ROS) and heat, enabling synergistic photodynamic therapy (PDT) and photothermal therapy (PTT), thereby sequentially triggering immunogenic cell death (ICD), activating the cGAS-STING pathway, and promoting vascular normalization. These cascade effects collectively promote dendritic cells (DCs), natural killer (NK) and T cell activation and infiltration, suppress regulatory T (Treg) cells, and reprogram both systemic and tumor immune microenvironments. Co-administration of the immune checkpoint inhibitor anti-TIGIT (aTIGIT), targeting phototherapy-induced exhausted TIGIT + NK cells, further potentiates antitumor efficacy. Metabolomic analysis reveals ITCC NP-induced reprogramming of tyrosine and lipid metabolism, potentially relieving immunosuppressive metabolic stress and enhancing antitumor immunity. In summary, ITCC NPs function as a single-component, NIR-activated nanoplatform that elicits synergistic phototherapeutic and immunomodulatory effects for cascade amplification of antitumor immunity. Their therapeutic potential is also validated in human hepatocellular carcinoma and breast cancer organoid models. This work presents a single-component, NIR-activated nanoplatform (ITCC NPs) that integrates synergistic photodynamic and photothermal therapies to sequentially induce immunogenic cell death, activate cGAS-STING signaling, and promote vascular normalization. Collectively, these processes remodel the immune microenvironment, achieving cascade-amplified antitumor immunity. When combined with anti-TIGIT immunotherapy, ITCC NPs significantly enhance therapeutic efficacy, representing a promising strategy for precision phototheranostics in cancer treatment. • Single-component ITCC NPs integrate PDT and PTT, achieving synergistic tumor ablation and enhanced antitumor immunity. • Sequential cascade-amplified immune activation via ICD induction, cGAS–STING pathway activation and vascular normalization. • Phototherapy-driven tumor metabolic reprogramming further augmented antitumor immune responses. • Combination with anti-TIGIT immune checkpoint blockade markedly enhanced in vivo antitumor efficacy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Immunotherapy and Immune Responses · Immune cells in cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (45)

Show source-provided references
1. Phototherapy in cancer treatment: strategies and challenges10.1038/s41392-025-02140-y ↗
2. ROS-catalytic self-amplifying benzothiophenazine-based photosensitive conjugates for photodynamic-immuno therapy10.1016/j.biomaterials.2025.123413 ↗
3. Reshaping the tumor immune microenvironment based on a light‐activated nanoplatform for efficient cancer therapy10.1002/adma.202108908 ↗
4. A polymer multicellular nanoengager for synergistic NIR‐II photothermal immunotherapy10.1002/adma.202008061 ↗
5. Smart nanomaterials for cancer diagnosis and treatment10.1186/s40580-022-00313-x ↗
6. Photoactivated in-situ engineered-bacteria as an efficient H2S generator to enhance photodynamic immunotherapy via remodeling the tumor microenvironment10.1016/j.biomaterials.2025.123388 ↗
7. Exosomes in the hypoxic TME: from release, uptake and biofunctions to clinical applications10.1186/s12943-021-01440-5 ↗
8. Hypoxia-inducible factors: cancer progression and clinical translation10.1172/JCI159839 ↗
9. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors10.1186/s12943-018-0759-3 ↗
10. Immunometabolic rewiring in tumorigenesis and anti-tumor immunotherapy10.1186/s12943-021-01486-5 ↗
11. Self-generating oxygen enhanced mitochondrion-targeted photodynamic therapy for tumor treatment with hypoxia scavenging10.7150/thno.36988 ↗
12. Precise regulation of reactive oxygen species in tumor microenvironment for alleviating inhibitory immunogenic cell death10.1002/adhm.202401741 ↗
13. Overcoming vascular barriers to improve the theranostic outcomes of nanomedicines10.1002/advs.202103148 ↗
14. Photovoltaic molecule‐based phototheranostics with A‐D‐A structure for near‐infrared fluorescence imaging‐guided synergetic photodynamic and photothermal therapy of tumors10.1002/bio.4930 ↗
15. Advances and perspectives in phototherapy-based combination therapy for cancer treatment10.1039/D4TB00483C ↗
16. How to improve photodynamic therapy-induced antitumor immunity for cancer treatment?10.7150/thno.72465 ↗
17. Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency10.1002/advs.202201734 ↗
18. Photoactivated theranostic nanomaterials based on aggregation‐induced emission luminogens for cancer photoimmunotherapy
19. Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future10.1136/jitc-2020-001926 ↗
20. The cGAS‒STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications10.1186/s13045-025-01691-5 ↗
21. cGAS/STING signalling pathway in senescence and oncogenesis10.1016/j.semcancer.2024.08.007 ↗
22. The cytosolic DNA-sensing cGAS–STING pathway in cancer10.1158/2159-8290.CD-19-0761 ↗
23. Photochemical bomb: precision nuclear targeting to activate cGAS-STING pathway for enhanced bladder cancer immunotherapy10.1016/j.biomaterials.2025.123126 ↗
24. Single-site nanozyme with exposed unsaturated Cu-O2 sites for tumor therapy by coordinating innate immunity and vasculature normalization10.1016/j.chempr.2024.08.020 ↗
25. In situ secondary self‐assembly of near‐infrared II j‐aggregates: a novel phototheranostic strategy for inducing tumor pyroptosis
26. Dual-phase nanoscissors disrupt vasculature-breast cancer stem cell crosstalk for breast cancer treatment10.1016/j.jconrel.2024.11.058 ↗
27. Bioorthogonal guided activation of cGAS‐STING by AIE photosensitizer nanoparticles for targeted tumor therapy and imaging10.1002/adma.202305668 ↗
28. Pyroptosis‐mediated synergistic photodynamic and photothermal immunotherapy enabled by a tumor‐membrane‐targeted photosensitive dimer
29. A self-assembling nanoplatform for pyroptosis and ferroptosis enhanced cancer photoimmunotherapy10.1038/s41377-024-01673-1 ↗
30. Indacenodithienothiophene-based A-D-A-type phototheranostics for immuno-phototherapy10.1186/s12951-025-03381-3 ↗
31. NIR-II emissive multifunctional AIEgen with single laser-activated synergistic photodynamic/photothermal therapy of cancers and pathogens10.1016/j.biomaterials.2020.120315 ↗
32. Near‐infrared materials: the turning point of organic photovoltaics10.1002/adma.202107330 ↗
33. Achieving highly efficient nonfullerene organic solar cells with improved intermolecular interaction and open‐circuit voltage10.1002/adma.201700254 ↗
34. A single‐atom Mn/MoO3− x nanoagonist for cascade cGAS/STING activation in tumor‐specific catalytic metalloimmunotherapy10.1002/smll.202407214 ↗
35. Tyrosine metabolic reprogramming coordinated with the tricarboxylic acid cycle to drive glioma immune evasion by regulating PD‐L1 expression10.1002/ibra.12107 ↗
36. Fatty acid metabolism of immune cells: a new target of tumour immunotherapy10.1038/s41420-024-01807-9 ↗
37. TGFβ drives NK cell metabolic dysfunction in human metastatic breast cancer10.1136/jitc-2020-002044 ↗
38. TIGIT in cancer immunotherapy10.1136/jitc-2020-000957 ↗
39. In situ STING‐activating nanovaccination with TIGIT blockade for enhanced immunotherapy of anti‐PD‐1‐resistant tumors10.1002/adma.202300171 ↗
40. Whole‐component antigen nanovaccines combined vith aTIGIT for enhanced innate and adaptive anti‐tumor immunity10.1002/smll.202412800 ↗
41. IL-21 collaborates with anti-TIGIT to restore NK cell function in chronic HBV infection10.1002/jmv.29142 ↗
42. Stimuli-responsive nano vehicle enhances cancer immunotherapy by coordinating mitochondria-targeted immunogenic cell death and PD-L1 blockade10.1016/j.apsb.2021.11.005 ↗
43. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions10.1186/s12943-021-01489-2 ↗
44. Individualized pathway activity algorithm identifies oncogenic pathways in pan-cancer analysis10.1016/j.ebiom.2022.104014 ↗
45. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective10.1038/s41392-022-01168-8 ↗